The Impact of Biologics and Biosimilars on Chronic Disease Management

Abstract

In the last 30 years, medicines containing live biological ingredients have changed the treatment of many diseases. Other than a few cancers, these medicines have cured rheumatoid arthritis, psoriasis, Crohn’s disease, multiple sclerosis, etc. Unlike traditional small-molecule medicines, which have general and varied effects, biologics have a much more specific action. They act more like a missile locking on to a target.  Many biologics have been launched as off-patent medicines which has ushered a greater number of such drugs Biosimilars are substances that act like a reference biologic. They are as good as the reference biologics in other words. The FDA says biosimilars must have similar genetic characteristics, this is important to guarantee that they are effective and safe. There have been a few biosimilars in the market and their availability is only increasing. An informative guide on biosimilars and biologics for providers and patients. Though these may curb healthcare costs, and enhance availability, the healthcare provider and patient awareness of biosimilars and biologics are vital as it safeguard modern medicine.  This study looks into the impact on therapy, money, and ethics caused by biosimilars and looks at chronic disease specifically.